These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 9571349)
1. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Tatti P; Pahor M; Byington RP; Di Mauro P; Guarisco R; Strollo G; Strollo F Diabetes Care; 1998 Apr; 21(4):597-603. PubMed ID: 9571349 [TBL] [Abstract][Full Text] [Related]
2. Effects of amlodipine fosinopril combination on microalbuminuria in hypertensive type 2 diabetic patients. Fogari R; Preti P; Zoppi A; Rinaldi A; Corradi L; Pasotti C; Poletti L; Marasi G; Derosa G; Mugellini A; Voglini C; Lazzari P Am J Hypertens; 2002 Dec; 15(12):1042-9. PubMed ID: 12460699 [TBL] [Abstract][Full Text] [Related]
3. Hypertension and diabetes and the Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET). More ammunition against surrogate end points. Califf RM; Granger CB Diabetes Care; 1998 Apr; 21(4):655-7. PubMed ID: 9571359 [No Abstract] [Full Text] [Related]
4. Comorbidity of hypertension and diabetes: the fosinopril versus amlodipine cardiovascular events trial (FACET). Sowers JR Am J Cardiol; 1998 Nov; 82(9B):15R-19R. PubMed ID: 9822138 [TBL] [Abstract][Full Text] [Related]
5. The Fosinopril versus Amlodipine Cardiovascular Events Trial (FACET) and combination therapies. Pahor M; Tatti P Am J Cardiol; 1999 Mar; 83(5):819-20. PubMed ID: 10080455 [No Abstract] [Full Text] [Related]
6. Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, randomized, double-blind, noninferiority study. Lee IT; Hung YJ; Chen JF; Wang CY; Lee WJ; Sheu WH Clin Ther; 2012 Aug; 34(8):1735-50. PubMed ID: 22784975 [TBL] [Abstract][Full Text] [Related]
7. New evidence on the prevention of cardiovascular events in hypertensive patients with type 2 diabetes. Pahor M; Psaty BM; Furberg CD J Cardiovasc Pharmacol; 1998; 32 Suppl 2():S18-23. PubMed ID: 9736437 [TBL] [Abstract][Full Text] [Related]
8. Fosinopril and amlodipine in the treatment of isolated systolic hypertension. Pavlović K; Benc D; Kmezić-Grujin J; Stojiljković J; Cemerlić-Adić N; Miljković T; Mesaros P Med Pregl; 2004; 57(1-2):45-53. PubMed ID: 15327190 [TBL] [Abstract][Full Text] [Related]
9. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Pahor M; Psaty BM; Alderman MH; Applegate WB; Williamson JD; Furberg CD Diabetes Care; 2000 Jul; 23(7):888-92. PubMed ID: 10895836 [TBL] [Abstract][Full Text] [Related]
11. Albuminuria and transferrinuria in essential hypertension. Effects of antihypertensive therapy. Alli C; Lombardo M; Zanni D; Agrati AM; Cassani M; Granata S Am J Hypertens; 1996 Nov; 9(11):1068-76. PubMed ID: 8931831 [TBL] [Abstract][Full Text] [Related]
12. CCBs vs ACE inhibitors in patients with diabetes. Zamorski MA J Fam Pract; 1998 Jul; 47(1):12-3. PubMed ID: 9673598 [No Abstract] [Full Text] [Related]
13. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Velussi M; Brocco E; Frigato F; Zolli M; Muollo B; Maioli M; Carraro A; Tonolo G; Fresu P; Cernigoi AM; Fioretto P; Nosadini R Diabetes; 1996 Feb; 45(2):216-22. PubMed ID: 8549868 [TBL] [Abstract][Full Text] [Related]
14. Antihypertensive pharmacogenetic effect of fibrinogen-beta variant -455G>A on cardiovascular disease, end-stage renal disease, and mortality: the GenHAT study. Lynch AI; Boerwinkle E; Davis BR; Ford CE; Eckfeldt JH; Leiendecker-Foster C; Arnett DK Pharmacogenet Genomics; 2009 Jun; 19(6):415-21. PubMed ID: 19352213 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Berl T; Hunsicker LG; Lewis JB; Pfeffer MA; Porush JG; Rouleau JL; Drury PL; Esmatjes E; Hricik D; Parikh CR; Raz I; Vanhille P; Wiegmann TB; Wolfe BM; Locatelli F; Goldhaber SZ; Lewis EJ; Ann Intern Med; 2003 Apr; 138(7):542-9. PubMed ID: 12667024 [TBL] [Abstract][Full Text] [Related]
16. Long-term effects of angiotensin-converting enzyme inhibitors and calcium antagonists on the right and left ventricles in essential hypertension. Lombardo M; Alli C; Broccolino M; Ferrari S; Montemurro L; Zaini G; Zanni D Am Heart J; 1997 Sep; 134(3):557-64. PubMed ID: 9327716 [TBL] [Abstract][Full Text] [Related]
17. Amlodipine versus angiotensin II receptor blocker; control of blood pressure evaluation trial in diabetics (ADVANCED-J). Kawamori R; Daida H; Tanaka Y; Miyauchi K; Kitagawa A; Hayashi D; Kishimoto J; Ikeda S; Imai Y; Yamazaki T BMC Cardiovasc Disord; 2006 Oct; 6():39. PubMed ID: 17029631 [TBL] [Abstract][Full Text] [Related]
18. Effects of a fixed-dose ACE inhibitor-diuretic combination on ambulatory blood pressure and arterial properties in isolated systolic hypertension. Ferguson JM; Minas J; Siapantas S; Komesaroff PA; Sudhir K J Cardiovasc Pharmacol; 2008 Jun; 51(6):590-5. PubMed ID: 18520951 [TBL] [Abstract][Full Text] [Related]
19. Comparative metabolic effects of hydrochlorothiazide and indapamide in hypertensive diabetic patients receiving ACE inhibitor therapy. Krum H; Skiba M; Gilbert RE Diabet Med; 2003 Sep; 20(9):708-12. PubMed ID: 12925048 [TBL] [Abstract][Full Text] [Related]
20. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Leenen FH; Nwachuku CE; Black HR; Cushman WC; Davis BR; Simpson LM; Alderman MH; Atlas SA; Basile JN; Cuyjet AB; Dart R; Felicetta JV; Grimm RH; Haywood LJ; Jafri SZ; Proschan MA; Thadani U; Whelton PK; Wright JT; Hypertension; 2006 Sep; 48(3):374-84. PubMed ID: 16864749 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]